Navigation Links
Acute Myeloid Leukemia Market (AML) – 2017 Opportunity Analysis and Forecast in New Research Report at ReportsnReports.com
Date:8/19/2013

Dallas, Texas (PRWEB) August 19, 2013

Acute myeloid (myelogenous, myelocytic) leukemia is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively rare, and predominantly affects older adults. AML is a heterogeneous disease, and many subtypes have been identified. The current standard of care consists of cytarabine-based chemotherapy, which can often achieve remission. However, the majority of patients relapse, and survival rates are grim. There are clear unmet needs for treatments that can prolong the overall survival of these patients, but drug manufacturers have struggled to gain regulatory approval for new therapies.

This report focuses on the remaining opportunity in AML (Acute Myeloid Leukemia - http://www.reportsnreports.com/reports/267301-opportunityanalyzer-acute-myeloid-leukemia-aml-opportunity-analysis-and-forecasts-to-2017.html) exclusive of the acute promyleocytic leukemia (APL) subtype.

Scope

  •     Overview of AML, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  •     Top-line AML therapeutics market revenue from 2012–2017. Annual cost of therapy, and peak pipeline drug sales of drugs launching during this forecast period are included.
  •     Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the AML therapeutics market.
  •     Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline drugs. An interactive clinical and commercial analyzer tool is available.
  •     Analysis of the current and future market competition in the global AML therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Findings

  •     The report forecasts the AML therapeutics market in the 6MM to grow from $151.0m in 2012 to $430.7m in 2017, at a CAGR of 23.3%. The main driver of growth in the global AML market will be the uptake of premium-priced pipeline agents.
  •     Despite high levels of unmet need, uptake of new drugs will be limited, as KOLs are relatively unimpressed by these agents. Therefore, ample market opportunity will remain at the end of the forecast period.
  •     To circumvent historical difficulties with regulatory approval, companies are designing early- and late-stage clinical trials more rigorously. Randomization of early-stage trials is critical, and the designation of overall survival (OS) as the primary endpoint of pivotal studies is mandatory.
  •     Key R&D trends include developing therapies for the patients with greatest unmet need, particularly the elderly, developing combination therapies, and investigating new targets (i.e. FLT3) involved in the pathogenesis of AML.
  •     Despite the hype around FLT3 inhibitors, KOLs are unconvinced that these drugs will be successful as monotherapies in AML.

Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=267301 . Alternatively can get DISCOUNT @ http://www.reportsnreports.com/contacts/discount.aspx?name=267301 .

Reasons to Buy

  •     Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  •     Develop business strategies by understanding the trends shaping and driving the global AML therapeutics market.
  •     Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AML therapeutics market in the future.
  •     Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  •     Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  •     Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Key Questions Answered

  •     Which AML patients have the greatest unmet needs?
  •     What are the R&D strategies drug makers are pursuing in the AML space?
  •     Why has it been so difficult for Pharma to develop successful therapies for AML?
  •     How are players aiming to circumvent difficulties that have historically plagued AML drug development?
  •     What are the most promising pipeline agents for AML? How do their clinical and commercial attributes compare to one another?
  •     What opportunities will remain following the launch of these pipeline agents?
  •     Do KOLs see a role for targeted therapies and immunotherapy’s in the treatment of AML?

Explore more reports on Pharmaceuticals Market @ http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us
ReportsnReports.com (http://www.reportsnreports.com/) is an online market research reports library of 200,000+ reports and in-depth studies of 5000+ micro markets. Our database includes reports by leading publishers from across the globe.

Read the full story at http://www.prweb.com/releases/acute-myeloid-leukemia/market-aml-2017-forecast/prweb11038556.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Long-term neuropsychological impairment is common in acute lung injury survivors
2. Predictors identified for rehospitalization among post-acute stroke patients
3. Original research papers on acute cardiovascular care: ESC launches EHJ-ACVC
4. A microRNA prognostic marker identified in acute leukemia
5. 4 acute mushroom poisonings in 2 weeks
6. Scientists identify possible drug target for acute pancreatitis
7. Inhibitors of shuttle molecule show promise in acute leukemia
8. Is acetazolamide effective and safe for preventing acute mountain sickness?
9. A new target in acute myeloid leukemia
10. Implementing a therapeutic hypothermia program for post-cardiac arrest in acute care hospitals
11. MDC researchers develop new approach to treat acute liver failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on his ... the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family ... hospital’s 30th heart transplant recipient. , “He was playing at home, when we got ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving back to ... fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. AlignLife ... children of the world. , In exchange for generous donations, customers will receive a ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers Delightful Holiday ... Up To 33% Off Botox® and Juvederm® Products Now Through December 31, 2016 , ... Delightful Deals on Botox® and Juvederm® just in time for the holiday party ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, ... medicines company, announced today that it entered into ... RNA-based therapeutics for the treatment of NASH and ... therapeutic delivery platform LUNAR™ and UNA Oligomer chemistry. ... "Given Takeda,s long-standing commitment to and expertise in ...
(Date:12/6/2016)... 2016  Regulus Therapeutics Inc. (NASDAQ: ... and development of innovative medicines targeting microRNAs, today ... R&D day, held in New York ... anti-miR targeting microRNA-27 (miR-27) for the treatment of ... anti-miR targeting microRNA-17 (miR-17) for the treatment of ...
(Date:12/6/2016)... A new study released today by the ... the 340B Drug Pricing Program will continue to expand at ... expected to exceed $23 billion in total purchases at the ... current Medicare Part B drug reimbursement purchases over the next ... on analysis of data on total drug purchases through 340B ...
Breaking Medicine Technology: